Skip to main content
Clinical Trials/IRCT201105186515N1
IRCT201105186515N1
Completed
Phase 2

Evaluation of effectiveness and safety of Magnesium Carbonate and comparison with calcium carbonate in hyperphosphatemic end stage renal disease patients on chronic hemodialysis.

Vice chancellor for research, Isfahan University of Medical Sciences0 sites50 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Condition 1: End stage renal disease. Condition 2: hyperphosphatemia.
Sponsor
Vice chancellor for research, Isfahan University of Medical Sciences
Enrollment
50
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice chancellor for research, Isfahan University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • age\>18 years; serum phosphorus \>5\.5 mg/dl; at least 3 months on hemodialysis.
  • exclusion criteria: serum magnesium \> 4 mg/dl; pregnancy; previous parathyroidectomy; sever hyperparathyroidism(iPTH\> 500 pg/ml); Medical disease cause diarrhea; Kidney transplant; Patient Death; Non\-compliance of drug usage (at least 80% of prescribed drug must be used); Drug complications making the patient unable to continue the treatment; Lost hemodialysis more than one per month or Irregular hemodialysis

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials